|Dr. Pardeep Nijhawan FRCPC, M.D.||CEO, Company Sec. & Director||165.15k||N/A||1970|
|Dr. Michael J. Brooks M.B.A., Ph.D.||Pres||259.91k||N/A||1978|
|Ms. Kathi Niffenegger CPA, CPA||Chief Financial Officer||N/A||N/A||1957|
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. The company was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.